Allinky has a pipeline of three novel and propietary small molecule programs in four major therapeutic areas: neuroprotection, cancer, inflammation and type II diabetes. For some of these programs we seek to partner with pharmaceutical companies that share our vision of innovation for targeting prevalent diseases at a molecular level. Reasons to partner with Allinky:
Tight academic collaborations that ensure cutting-
Technology platform that integrates the drug discovery activities
New mode of actions on validated targets to attain first-
If you wish to partner with Allinky please get in contact with us.